We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Deere, BHP Group and Manulife Financial
Read MoreHide Full Article
For Immediate Release
Chicago, IL – May 21, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk AS (NVO - Free Report) , International Business Machines Corporation (IBM - Free Report) , Deere & Company (DE - Free Report) , BHP Group (BHP - Free Report) and Manulife Financial Corporation (MFC - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports on Novo Nordisk, IBM and Deere & Co.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk, International Business Machines, and Deere. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry in the last one-year period (+23.4% vs. +11.8%). In fact, Novo Nordisk’s earnings and revenues beat estimates in Q1. What’s more, Ozempic is off to a solid start and the launch of Rybelsus also looks impressive, per the Zacks analyst.
Victoza, Ozempic, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of existing drugs will further boost sales. In 2021, the company will continue its focus on commercial execution while conducting more late-stage clinical studies than ever to meet the needs of the people living with diabetes and other serious chronic diseases.
However, lower realized prices in the Unites States, loss of exclusivity for products in hormone replacement therapy and intensifying competition will affect sales. Sales are also being negatively impacted by COVID-19-related stocking, which remains a woe.
Shares of IBM have outperformed the Zacks Computer - Integrated Systems industry in the year-to-date period (+13.8% vs. +12.4%). The Zacks analyst believes that IBM is well-poised to benefit from solid uptake of the company’s cloud-based solutions. Synergies from Red Hat buyout are strengthening its competitive position in the hybrid cloud market.
The company is also likely to gain from spin-off of legacy infrastructure services business as it focuses on its hybrid cloud strategy. Strong patent portfolio and healthy uptake of IBM’s blockchain, security and other digital transformation offerings bode well in the long haul.
Nonetheless, intense competition in the cloud computing market from the likes of Amazon Web Services and Microsoft Azure is a major headwind. Higher debt levels amid extensive restructuring activities are other concerns.
Shares of Deere have gained +33.2% in the year-to-date period against the Zacks Manufacturing - Farm Equipment industry’s gain of +29.7%. Deere expects net income for fiscal 2021 between $4.6 billion and $5 billion backed by improving conditions in the farm and construction sectors.
The mid-point of the range suggests year-over-year improvement of 75%. Pick-up in commodity prices bodes well for agricultural equipment demand. Further, replacement demand triggered by the need to replace old equipment will continue to boost the company's revenues.
The Zacks analyst believes that Deere’s focus on investing in new products with advanced technologies provides it a competitive edge. Additionally, the company's concerted efforts to expand in precision agriculture will drive growth in the long haul.
Other noteworthy reports we are featuring today include BHP Group and Manulife Financial Corp.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Deere, BHP Group and Manulife Financial
For Immediate Release
Chicago, IL – May 21, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk AS (NVO - Free Report) , International Business Machines Corporation (IBM - Free Report) , Deere & Company (DE - Free Report) , BHP Group (BHP - Free Report) and Manulife Financial Corporation (MFC - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports on Novo Nordisk, IBM and Deere & Co.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk, International Business Machines, and Deere. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry in the last one-year period (+23.4% vs. +11.8%). In fact, Novo Nordisk’s earnings and revenues beat estimates in Q1. What’s more, Ozempic is off to a solid start and the launch of Rybelsus also looks impressive, per the Zacks analyst.
Victoza, Ozempic, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of existing drugs will further boost sales. In 2021, the company will continue its focus on commercial execution while conducting more late-stage clinical studies than ever to meet the needs of the people living with diabetes and other serious chronic diseases.
However, lower realized prices in the Unites States, loss of exclusivity for products in hormone replacement therapy and intensifying competition will affect sales. Sales are also being negatively impacted by COVID-19-related stocking, which remains a woe.
(You can read the full research report on Novo Nordisk here >>>)
Shares of IBM have outperformed the Zacks Computer - Integrated Systems industry in the year-to-date period (+13.8% vs. +12.4%). The Zacks analyst believes that IBM is well-poised to benefit from solid uptake of the company’s cloud-based solutions. Synergies from Red Hat buyout are strengthening its competitive position in the hybrid cloud market.
The company is also likely to gain from spin-off of legacy infrastructure services business as it focuses on its hybrid cloud strategy. Strong patent portfolio and healthy uptake of IBM’s blockchain, security and other digital transformation offerings bode well in the long haul.
Nonetheless, intense competition in the cloud computing market from the likes of Amazon Web Services and Microsoft Azure is a major headwind. Higher debt levels amid extensive restructuring activities are other concerns.
(You can read the full research report on IBM here >>>)
Shares of Deere have gained +33.2% in the year-to-date period against the Zacks Manufacturing - Farm Equipment industry’s gain of +29.7%. Deere expects net income for fiscal 2021 between $4.6 billion and $5 billion backed by improving conditions in the farm and construction sectors.
The mid-point of the range suggests year-over-year improvement of 75%. Pick-up in commodity prices bodes well for agricultural equipment demand. Further, replacement demand triggered by the need to replace old equipment will continue to boost the company's revenues.
The Zacks analyst believes that Deere’s focus on investing in new products with advanced technologies provides it a competitive edge. Additionally, the company's concerted efforts to expand in precision agriculture will drive growth in the long haul.
(You can read the full research report on Deere here >>>)
Other noteworthy reports we are featuring today include BHP Group and Manulife Financial Corp.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.